Krister Bamberg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2652431/publications.pdf

Version: 2024-02-01

28	3,181	394421	501196
papers	citations	19 h-index	28 g-index

28	28	28	5227
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Discovery by Virtual Screening of an Inhibitor of CDK5-Mediated PPARÎ³ Phosphorylation. ACS Medicinal Chemistry Letters, 2022, 13, 681-686.	2.8	9
2	Electrolyte handling in the isolated perfused rat kidney: demonstration of vasopressin V2-receptor-dependent calcium reabsorption. Upsala Journal of Medical Sciences, 2020, 125, 274-280.	0.9	1
3	Molecular tuning of farnesoid X receptor partial agonism. Nature Communications, 2019, 10, 2915.	12.8	71
4	The selective mineralocorticoid receptor modulator AZD9977 reveals differences in mineralocorticoid effects of aldosterone and fludrocortisone. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2019, 20, 147032031982744.	1.7	9
5	Identification of Mineralocorticoid Receptor Modulators with Low Impact on Electrolyte Homeostasis but Maintained Organ Protection. Journal of Medicinal Chemistry, 2019, 62, 1385-1406.	6.4	15
6	Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator. British Journal of Clinical Pharmacology, 2018, 84, 1486-1493.	2.4	16
7	Na restriction activates epithelial Na channels in rat kidney through two mechanisms and decreases distal Na⁺ delivery. Journal of Physiology, 2018, 596, 3585-3602.	2.9	20
8	Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS ONE, 2018, 13, e0193380.	2.5	46
9	Structureâ€Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity. ChemMedChem, 2017, 12, 50-65.	3.2	13
10	Nephropathy in Pparg-null mice highlights PPARÎ³ systemic activities in metabolism and in the immune system. PLoS ONE, 2017, 12, e0171474.	2.5	34
11	The peroxisome proliferator-activated receptor Î± agonist, AZD4619, induces alanine aminotransferase-1 gene and protein expression in human, but not in rat hepatocytes: Correlation with serum ALT levels. International Journal of Molecular Medicine, 2016, 38, 961-968.	4.0	3
12	An additive effect of eplerenone to ACE inhibitor on slowing the progression of diabetic nephropathy in the db/db mice. American Journal of Translational Research (discontinued), 2016, 8, 1339-54.	0.0	21
13	LT175 Is a Novel PPARÎ±/Î³ Ligand with Potent Insulin-sensitizing Effects and Reduced Adipogenic Properties. Journal of Biological Chemistry, 2014, 289, 6908-6920.	3.4	33
14	Gut Microbiota Regulates Bile Acid Metabolism by Reducing the Levels of Tauro-beta-muricholic Acid, a Naturally Occurring FXR Antagonist. Cell Metabolism, 2013, 17, 225-235.	16.2	1,671
15	Ageing Fxr Deficient Mice Develop Increased Energy Expenditure, Improved Glucose Control and Liver Damage Resembling NASH. PLoS ONE, 2013, 8, e64721.	2.5	57
16	Tesaglitazar, a PPARÎ±/Î³ Agonist, Induces Interstitial Mesenchymal Cell DNA Synthesis and Fibrosarcomas in Subcutaneous Tissues in Rats. Toxicological Sciences, 2007, 98, 63-74.	3.1	29
17	Gene expression analysis suggests that EBF-1 and PPARÎ³2 induce adipogenesis of NIH-3T3 cells with similar efficiency and kinetics. Physiological Genomics, 2005, 23, 206-216.	2.3	53
18	Regulation of hepatic metabolic pathways by the orphan nuclear receptor SHP. EMBO Journal, 2005, 24, 2624-2633.	7.8	129

#	Article	IF	Citations
19	Identification of the human ApoAV gene as a novel RORÎ± target gene. Biochemical and Biophysical Research Communications, 2005, 330, 233-241.	2.1	34
20	Differential regulation of cytosolic and peroxisomal bile acid amidation by PPARÎ± activation favors the formation of unconjugated bile acids. Journal of Lipid Research, 2004, 45, 1051-1060.	4.2	34
21	Expression of the Insulin-responsive Glucose Transporter GLUT4 in Adipocytes Is Dependent on Liver X Receptor Î±. Journal of Biological Chemistry, 2003, 278, 48283-48291.	3.4	149
22	On the Role of Liver X Receptors in Lipid Accumulation in Adipocytes. Molecular Endocrinology, 2003, 17, 172-182.	3.7	136
23	AZ 242, a novel PPARÎ±/Î³ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. Journal of Lipid Research, 2002, 43, 1855-1863.	4.2	105
24	Early B-Cell Factor (O/E-1) Is a Promoter of Adipogenesis and Involved in Control of Genes Important for Terminal Adipocyte Differentiation. Molecular and Cellular Biology, 2002, 22, 8015-8025.	2.3	105
25	Structure of the PPARÎ± and -Î³ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR Family. Structure, 2001, 9, 699-706.	3.3	301
26	Î²-Subunit Assembly Is Essential for the Correct Packing and the Stable Membrane Insertion of the H,K-ATPase Î±-Subunit. Journal of Biological Chemistry, 1999, 274, 8217-8223.	3.4	43
27	Structural Aspects of the Gastric H, K ATPase. Annals of the New York Academy of Sciences, 1997, 834, 65-76.	3.8	34
28	The expression of pepsinogen c mRNA in normal gastroduodenal mucosa and the gastric ulcer margin of the rat. Histochemistry and Cell Biology, 1996, 105, 163-169.	1.7	10